PYXS Pyxis Oncology, Inc.
USHealthcareAs of 2026-08-24
Why PYXS matters now
Pyxis Oncology, Inc. (PYXS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.96 with -3.90% on the session and $187.5M in market capitalization; recent performance reads 1-month +6.28% and YTD +76.52%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.3M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.1%.
The latest indexable market news headline is "Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Palani Santhosh filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.12
P/S
9.28
EV/EBITDA
-1.84
DCF Value
$1.74
FCF Yield
-52.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.8%
Operating Margin
-619.6%
Net Margin
-589.8%
ROE
-135.6%
ROA
-127.1%
ROIC
-173.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.3M | $-0.37 |
| Q4 2025 | $11.0M | $-18.1M | $-0.29 |
| FY 2025 | $13.9M | $-79.6M | $-1.28 |
| Q3 2025 | $0.00 | $-22.0M | $-0.35 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.43
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.